At the SOC level, besides nervous system disorders (≥ 2 cases), general disorders and administration site conditions (N = 2360, 29.62%), gastrointestinal disorders (N = 1764, 22.14%), and musculoskeletal and connective tissue disorders (N = 1616, 20.28%) were the top 3 reported co‐reported AEs, appearing in over 20% of PD‐1 inhibitors‐induced nAes (Figure 4c). Here, PDCD1 is linked to nervous system disorder.